

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No securities may be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Any public offering of securities to be made in the United States will be made by means of a prospectus. Such prospectus will contain detailed information about the company making the offer, its management, as well as financial statements. No public offer of securities is to be made by the Company in the United States.*



## **Yestar Healthcare Holdings Company Limited**

**巨星醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2393)**

### **COMPLETION NOTICE; ISSUANCE OF US\$197,864,523 SENIOR NOTES DUE 2026**

This announcement is made by Yestar Healthcare Holdings Company Limited (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated 8 November, 3 December, 12 December, 14 December and 29 December 2021 in relation to the Scheme (the “**Announcements**”). Unless otherwise defined herein, capitalised terms and expressions used in this announcement shall have the same meaning as defined in the Announcements and the explanatory statement dated 8 November 2021 relating to the Scheme.

The Company is hereby pleased to announce that:

- (i) each of the Restructuring Conditions has been satisfied and the Restructuring Effective Date occurred on 30 December 2021;

- (ii) on the Restructuring Effective Date: (a) the New Global Notes (ISINs: XS2407822274 (RegS); XS2407822357 (144A); XS2407823249 (IAI)) have been issued by the Company; and (b) the Company has instructed that the Consent Fee, the Scheme Consideration and the Residual New Notes be distributed to the relevant clearing system accounts of the applicable participants and the Holding Period Trustee (as applicable) in accordance with the terms of the Scheme;
- (iii) the Global Notes representing the Existing Notes (ISIN: XS1485533944) have been cancelled as of 31 December 2021;
- (iv) the New Notes have been listed on the Singapore Exchange Securities Trading Limited on 31 December 2021;
- (v) the Bar Time, which is the final deadline for a Scheme Creditor to submit the documentation required to receive the Scheme Consideration on the Holding Period Expiry Date in accordance with the terms of the Scheme, will be 7 a.m. (Cayman Islands time)/8 p.m. (Hong Kong time) on 25 March 2022. If an Ineligible Scheme Creditor fails to establish its entitlement to the Trust Assets in accordance with the terms of the Holding Period Trust Deed prior to the Bar Time, that Ineligible Scheme Creditor shall not be entitled to receive any Scheme Consideration under the Scheme. Any Scheme Creditor that has not already done this should refer to the Scheme Website (<https://sites.dfkingltd.com/yestar>) and, in particular, the Account Holder Letter for further details; and
- (vi) the Holding Period Expiry Date, which is the latest date on which the Trust Assets can be distributed in accordance with the terms of the Holding Period Trust Deed, will be 30 March 2022.

**FOR ASSISTANCE, PLEASE CONTACT**

**D.F. King Ltd**

Attention: D.F. King Debt Team

Telephone: in Hong Kong +852 3953 7208; in London: +44 20 7920 9700;

Email: [yestar@dfkingltd.com](mailto:yestar@dfkingltd.com)

Further announcement(s) will be made by the Company to inform the shareholders and potential investors of any material development as and when appropriate.

**Shareholders and investors are reminded to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Yestar Healthcare Holdings Company Limited**  
**Hartono James**  
*Chairman, CEO and Executive Director*

31 December 2021

*As at the date of this announcement, the executive Directors are Mr. Hartono James, Ms. Wang Hong, Ms. Liao Changxiang and Mr. Liang Junxiong; the independent non-executive Directors are Dr. Hu Yiming, Mr. Zeng Jinsong and Mr. Sutikno Liky.*